Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital

Early-stage MedTech gets riskier when investors confuse a compelling story with a credible device. Stronger diligence starts by testing whether the science is real, whether clinicians would actually use the product, and whether the company has thought seriously about regulatory fit, reimbursement logic, and engineering durability.That framework becomes even more important in neurotech, where public fascination can outrun the evidence base and where the difference between a breakthrough and a weak claim is often diligence quality.Episode Breakdown00:00 Opening02:42 Science and engineering filters07:55 Why neurotech still has open space17:15 Cybersecurity as a hardening issue24:20 How specialist funds operate38:13 Final reflections40:58 EndThe Med Device Cyber Podcast is brought to you by Blue Goat Cyber, cybersecurity experts providing essential security solutions for the medical device industry. Learn more by visiting https://bluegoatcyber.com.If you're interested in our services or partnering with us, schedule a Discovery Session: https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-sessionChristian Espinosa is the CEO and founder of Blue Goat Cyber. Trevor Slattery is the Chief Operating Officer at Blue Goat Cyber.Christian Espinosa on LinkedIn: https://www.linkedin.com/in/christianespinosa/Trevor Slattery on LinkedIn: https://www.linkedin.com/in/trevor-slattery-34852b1a9Blue Goat Cyber on LinkedIn: https://www.linkedin.com/company/blue-goat-cyber/Blue Goat Cyber on Instagram: https://www.instagram.com/bluegoatcyber/Blue Goat Cyber on Facebook: https://www.facebook.com/bluegoatcyber/Blue Goat Cyber on YouTube: https://www.youtube.com/@BlueGoatCyber/?sub_confirmation=1